BBLGHealthcare · BiotechnologyBBLG Stock Forecast: Bone Biologics Corp. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
BBLG stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Bone Biologics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (0): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Bone Biologics Corp. — and when they’d sell — is the membership.
BBLG stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BBLG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Apr 2023 | EF Hutton | Reiterates | Buy | $2.25 |
| 3 Apr 2023 | EF Hutton | Reiterates | Buy | $2.25 |
| 18 Oct 2022 | EF Hutton | Initiates | Buy | $2.25 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BBLG analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Bone Biologics Corp. (BBLG) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.1×
- Price / sales
- —
- Price / book
- 0.3×
- EV / EBITDA
- 0.9×
Cheaper than 72% of US stocks
Cheaper than 87% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −75.4%
- Return on assets
- −46.1%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
BBLG vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BBLG appears on the weeks it earns a place.
Frequently asked questions about BBLG stock
How does Ticker Nerd's model rank BBLG?
As at 1 Aug 2026, Bone Biologics Corp. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
What is the BBLG stock forecast for 2030?
No analyst covering Bone Biologics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBLG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
How has BBLG stock performed over the past year?
Bone Biologics Corp. returned -67.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bone Biologics Corp. do?
Bone Biologics Corporation is a medical device company specializing in bone regeneration for spinal fusion procedures. Its core technology revolves around the NELL-1 platform, featuring recombinant human NELL-1 protein that offers target-specific control over bone growth.
About Bone Biologics Corp.
Bone Biologics Corporation is a medical device company specializing in bone regeneration for spinal fusion procedures. Its core technology revolves around the NELL-1 platform, featuring recombinant human NELL-1 protein that offers target-specific control over bone growth. The lead product, NB1, combines rhNELL-1 with demineralized bone matrix to serve as a bone graft in spinal fusion surgeries, particularly for degenerative disc disease and lumbar interbody fusion. This technology also applies to orthopedic surgeries, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine, addressing skeletal bone defects and related conditions. Bone Biologics Corporation targets spine surgeons and patients requiring enhanced bone healing outcomes. It holds a license agreement with the UCLA Technology Development Group for developing and commercializing NELL-1 in spinal fusion. Founded in 2004 and headquartered in Burlington, Massachusetts, the company operates within the healthcare sector's medical devices industry, focusing on orthobiologic solutions for spine fusion markets.
CEO Mr. Jeffrey Frelick · 2 employees · United States · https://www.bonebiologics.com